Antiplatelet and anticoagulant therapy in patients with atrial fibrillation

Cardiology Review

Volumn 23, Issue 2, 2006, Pages 44-48

  Perez Gomez, Francisco ^a   Fernández, Cristina ^a  

^a HOSPITAL CLÍNICO SAN CARLOS   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; PROSTAGLANDIN SYNTHASE INHIBITOR; TRIFLUSAL; WARFARIN;

ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; BRAIN HEMORRHAGE; DRUG EFFICACY; HEART ATRIUM ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HUMAN; INTERNATIONAL NORMALIZED RATIO; MAJOR CLINICAL STUDY; MITRAL VALVE STENOSIS; OCCLUSIVE CEREBROVASCULAR DISEASE; RHEUMATIC HEART DISEASE; STOMACH HEMORRHAGE; STROKE; THROMBOEMBOLISM; THROMBOSIS PREVENTION; TREATMENT OUTCOME;

EID: 33644603665     PISSN: 10926607     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke. 1991;22(8):983-988.
2. Hart RG, Benavente O, McBride R, et al. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis. Ann Intern Med. 1999;131(7): 492-501.
3. van Walraven C, Hart RG, Singer DE, et al. Oral anticoagulants vs aspirin in nonvalvular atrial fibrillation: an individual patient meta-analysis. JAMA. 2002;88(19): 2441-2448.
4. Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III randomised clinical trial. Lancet. 1996;348(9028):633- e38.
5. Gullov AL, Koefoed BG, Petersen P, et al. Fixed minidose warfarin and aspirin alone and in combination vs adjusted-dose warfarin for stroke prevention in atrial fibrillation: Second Copenhagen Atrial Fibrillation, Aspirin, and Anticoagulation Study. Arch Intern Med. 1998;158(14):1513-1521.
6. Matías-Guiu J, Ferro JM, Alvarez-Sabín J, et al. Comparison of triflusal and aspirin for prevention of vascular events in patients after cerebral infarction: the TAQP Study: a randomised, double-blind, multicenter trial. Stroke. 2003;34(4):840-848.
7. Hurlen M, Abdelnoor M, Smith P, et al. Warfarin, aspirin, or both after myocardial infarction. N Engl J Med. 2002;347(13): 969-974.
8. Capelleri JC, Fiore LD, Brophy MT, et al. Efficacy and safety of combined anticoagulant and antiplatelet therapy versus anticoagulant monotherapy after mechanical heart valve replacement: a meta-analysis. Am Heart J. 1995;130(3 pt 1):547-552.
9. Salem DN, Stein PD, Al-Ahmad A, et al. Antithrombotic therapy in valvular heart disease-native and prosthetic: the Seventh ACCP Conference on Antithrombotic and Thrombolitic Therapy. Chest. 2004;126(3 suppl):457S-482S.
10. Turpie AG, Gent M, Laupacis A, et al. A comparison of aspirin with placebo in patients treated with warfarin after heart-valve replacement. N Engl J Med. 1993;329(8):524-529.
11. Loeliger EA, Poller L, Samama M, et al. Questions and answers on prothrombin time standardisation in oral anticoagulant control. Thromb Haemost. 1985;54(2): 515-517.
12. Fuster V, Ryden LE, Asinger RW, et al. ACC/AHA/ESC Guidelines for the Management of Patients With Atrial Fibrillation: Executive Summary. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to Develop Guidelines for the Management of Patients With Atrial Fibrillation) developed in collaboration with the North American Society of Pacing and Electrophysiology. Circulation. 2001;104(17): 2118-2150.
13. Secondary prevention in nonrheumatic atrial fibrillation after transient ischemic attack or minor stroke. EAFT (European Atrial Fibrillation Trial) Study Group. Lancet. 1993;342(8882):1255-1262.